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Organ-specific autoimmune disorders are
often associated with celiac disease (CD)
(1,2). Most studies investigated the fre-
quency of CD humoral autoimmunity in
patients at diagnosis of an organ-specific
autoimmune disorder or along its course.
Conversely, only two studies, dating back
to the early 2000s, were aimed at deter-
mining the frequency and co-occurrence
of organ-specific autoimmunity in CD
patients at diagnosis (3,4). These studies
reported discordant, excessively high
positivities for diabetes-specific autoim-
munity (12.2% and 31.6%, respectively)
that may be explained by the small num-
ber of patients investigated and the use
of, at least in part, outdated techniques
such as islet cell autoantibody assay.
On thesebases, our aimwas toevaluate
in a large cohort of CD patients at diagno-
sis the real frequency and co-occurrence
of humoral immunoreactivity specific of
four organ-specific autoimmune disorders
known to be associated to CD, namely,
type 1 diabetes (T1D), autoimmune thy-
roid disease (HT), autoimmune atrophic
gastritis (AG), and Addison disease (AD).
In particular, the immune response di-
rected against insulin (INS), GAD, tyrosine
phosphatase 2(aa 605-979) (IA-2), zinc cation
efflux transporter (ZnT8), thyroid peroxi-
dase, enzyme steroid 21-hydroxylase,
and parietal cells was investigated in 529
biopsy-confirmed CD patients at disease
diagnosis (332 girls/197 boys, age range
3.0–17.7 years) and compared with
that found in 264 anti-transglutaminase
autoantibody–negative healthy control
subjects (104 girls/160 boys; age range
3.0–18.0 years).
Of 529 CD patients, 11.7% were posi-
tive for at least one of the organ-specific
Figure 1—The upper part of the figure shows the frequencies of CD patients and healthy control
subjects positive for at least one of the organ-specific autoantibodies (Abs) investigated in the
study. The lower part of the figure shows the frequency distribution of the organ-specific
autoantibody-positive CD patients and healthy control subjects according to each single disease.
21(OH), steroid 21-hydroxylase; APC, parietal cell; TPO, thyroid peroxidase.
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antibodies investigated (Fig. 1) more
frequently than control subjects (6.4%,
P 5 0.023), with T1D-specific immune
response significantly higher compared
with HT and adrenal (2.1%, P 5 0.006
and 0.6%, P , 0.0001, respectively) but
not gastric immunoreactivities (4.2%).
Only 4.8% of autoantibody-positive
CD patients showed more than one
disease-specific immunoreactivity. Among
CD T1D-specific immunoreactivities,
GAD autoantibodies were significantly
more frequent (62.1%) relative to INS,
IA-2, and ZnT8 autoantibodies (31.0%,
P 5 0.034; 20.7%, P 5 0.003; and
13.8%, P 5 0.0003, respectively). More
than 20% of CD patients with T1D au-
toimmunity were positive for two to
three related autoantibodies. A high
percentage of CD patients (91.9%),
which includes among others all of the
T1D, AG, and AD autoantibody-positive
patients, did not present with the
clinical signs of the related disease.
Organ-specific autoantibody-positive
CD patients increased with age at diag-
nosis (P for trend 5 0.018). The overall
frequency of organ-specific autoim-
munity in CDboys/girls and symptomatic/
asymptomatic patients was not signifi-
cantly different.
The finding that about one of every
nine CD patients was positive for at least
one T1D-, HT-, AG-, or adrenal-specific hu-
moral autoantibody demonstrates the im-
portance to evaluate the organ-specific
autoimmunity at CD diagnosis. Our results
revalue downward the prevalences re-
ported so far in literature, which date
back to the early 2000s. Most of the
organ-specific autoantibody-positive CD
patients identified in this study were not
diagnosed for, but are just at risk to
develop, an organ-specific disease. In
this light, it will be extremely important
for future evaluation of the gluten-
withdrawal effects on the development
of organ-specific diseases after CD diagno-
sis. Finally, our data provide thefirst exper-
imental confirmation of the hypothesis (5)
that age at diagnosis is the only significant
predictor variable of developing an addi-
tional autoimmune disease in CD patients.
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